LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

3.26 4.15

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.12

Максимум

3.36

Ключови измерители
By Trading Economics
Приходи	-2M -13M
Служители	42
EBITDA	-2.1M -13M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+530.91% upside

Дивиденти
By Dow Jones
Следващи печалби	25.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-662M 307M
Предишно отваряне	-0.89
Предишно затваряне	3.26

Настроения в новините

By Acuity

50%

171 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.11.2025 г., 22:42 ч. UTC

Пазарно говорене

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

21.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.11.2025 г., 21:47 ч. UTC

Пазарно говорене

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21.11.2025 г., 21:43 ч. UTC

Пазарно говорене

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21.11.2025 г., 20:18 ч. UTC

Пазарно говорене

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21.11.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21.11.2025 г., 19:48 ч. UTC

Пазарно говорене

Precious Metals Fall for the Week -- Market Talk

21.11.2025 г., 19:44 ч. UTC

Печалби

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21.11.2025 г., 19:37 ч. UTC

Пазарно говорене

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21.11.2025 г., 19:27 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

21.11.2025 г., 19:27 ч. UTC

Пазарно говорене

Печалби

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21.11.2025 г., 19:20 ч. UTC

Пазарно говорене

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21.11.2025 г., 18:44 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21.11.2025 г., 18:37 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21.11.2025 г., 18:34 ч. UTC

Пазарно говорене

Печалби

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21.11.2025 г., 18:28 ч. UTC

Печалби

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21.11.2025 г., 18:03 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21.11.2025 г., 17:24 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

21.11.2025 г., 17:24 ч. UTC

Пазарно говорене

Intuit Seen on Path to Increase Growth -- Market Talk

21.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.11.2025 г., 17:05 ч. UTC

Пазарно говорене

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21.11.2025 г., 16:56 ч. UTC

Пазарно говорене

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21.11.2025 г., 16:47 ч. UTC

Пазарно говорене

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21.11.2025 г., 16:35 ч. UTC

Придобивния, сливания и поглъщания

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21.11.2025 г., 16:09 ч. UTC

Печалби

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21.11.2025 г., 15:59 ч. UTC

Пазарно говорене

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

21.11.2025 г., 15:59 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.11.2025 г., 15:23 ч. UTC

Пазарно говорене

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

21.11.2025 г., 15:17 ч. UTC

Пазарно говорене

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

530.91% нагоре

12-месечна прогноза

Среден 20 USD 530.91%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

171 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.